ARS Pharmaceuticals
ARS Pharmaceuticals is dedicated to developing patient-friendly, needle-free treatments for severe allergic reactions, including an investigational intranasal epinephrine spray called neffy. The company aims to provide a reliable, easy-to-use alternative to traditional epinephrine auto-injectors, with a focus on safety, convenience, and rapid administration. ARS is advancing its product through clinical development and regulatory review, with a mission to improve emergency treatment options for allergy sufferers.
Industries
Nr. of Employees
medium (51-250)
ARS Pharmaceuticals
Patents
Products
neffy (epinephrine nasal spray)
An intranasal epinephrine spray developed to provide rapid systemic absorption comparable to intramuscular epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis.
neffy
Neffy is a needle-free epinephrine nasal spray used for the emergency treatment of allergic reactions including anaphylaxis in adults and children who weigh 33 lbs or greater.
neffy (epinephrine nasal spray)
An intranasal epinephrine spray developed to provide rapid systemic absorption comparable to intramuscular epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis.
neffy
Neffy is a needle-free epinephrine nasal spray used for the emergency treatment of allergic reactions including anaphylaxis in adults and children who weigh 33 lbs or greater.
Expertise Areas
- Intranasal drug delivery development
- Pharmacokinetics and bioequivalence assessment
- Clinical trial design and registration programs
- Regulatory affairs (FDA and EMA submissions and designations)
Key Technologies
- Intranasal/mucosal drug delivery
- Nasal absorption-enhancing excipients
- Pharmacokinetic (PK) and pharmacodynamic (PD) assays
- Bioequivalence study design
News & Updates
A conference call to discuss the merger and the potential commercialization of neffy, ARS’s needle-free epinephrine nasal spray.
The U.S. Patent and Trademark Office issued a second key patent for ARS-1, a low dose intranasal epinephrine nasal spray, covering fast-acting decreased dosage level for type 1 allergic reactions.
A patent covering a fast-acting decreased dosage level for intranasal administration for type 1 allergic reactions, issued by the USPTO on June 16, 2020.
A conference call to discuss the merger and the potential commercialization of neffy, ARS’s needle-free epinephrine nasal spray.
The U.S. Patent and Trademark Office issued a second key patent for ARS-1, a low dose intranasal epinephrine nasal spray, covering fast-acting decreased dosage level for type 1 allergic reactions.
A patent covering a fast-acting decreased dosage level for intranasal administration for type 1 allergic reactions, issued by the USPTO on June 16, 2020.